adamantane has been researched along with Infection in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iwasaki, M; Izutsu, H; Kaneko, Y; Katayama, K; Kawakami, A; Rokuda, M; Shiomi, T; Takeuchi, T; Tanaka, S; Tanaka, Y; Ushijima, S; van der Heijde, D; Yamada, E | 1 |
| Akazawa, R; Chen, YH; Iwasaki, M; Izutsu, H; Kaneko, Y; Kawakami, A; Lee, SH; Rokuda, M; Shiomi, T; Song, YW; Takeuchi, T; Tanaka, S; Tanaka, Y; Ushijima, S; Wei, JC; Yamada, E | 1 |
2 trial(s) available for adamantane and Infection
| Article | Year |
|---|---|
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.
Topics: Adamantane; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Substitution; Female; Herpes Zoster; Humans; Immunosuppressive Agents; Infections; Janus Kinase Inhibitors; Japan; Male; Methotrexate; Middle Aged; Niacinamide; Severity of Illness Index; Treatment Outcome | 2019 |
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Topics: Adamantane; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Double-Blind Method; Drug Substitution; Female; Herpes Zoster; Humans; Immunosuppressive Agents; Infections; Janus Kinase Inhibitors; Japan; Male; Middle Aged; Niacinamide; Severity of Illness Index; Treatment Outcome | 2019 |